CINJALL: Treatment for Children With Acute Lymphocytic Leukemia
Outline of Therapy:
Combinations of chemotherapy drugs will be given orally, intravenously and intrathecally
(directly into the cerebrospinal fluid by spinal tap) over a period of roughly two and a
Therapy will be divided into five phases:
Induction (4 weeks): chemotherapy given to produce a clinical remission (defined by normal
blood counts, with the absence of leukemia cells in the blood and fewer than 5% leukemia
cells in the bone marrow).
Consolidation (11 weeks): chemotherapy given to consolidate the remission. Delayed
Intensification (7 weeks) Intensive chemotherapy aimed at killing any resistant leukemia
cells will be given only for patients at high risk of relapse.
Intensive Continuation (approximately 1 year): Eight week cycles of chemotherapy, given
Continuation (final year of therapy): Eight week cycles of largely oral chemotherapy, with
one clinic visit for a lumbar puncture every eight weeks.
Irradiation: radiation will be given in the middle of intensive continuation to the head and
spine of those patients who have leukemia cells found in the cerebrospinal fluid at the time
Follow-up: After the conclusion of therapy, there will be periodic office visits, initially
monthly, then gradually spaced out to annual visits. The purpose of these visits is to
evaluate for late side-effects of therapy.
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The purpose of this research study is to identify better ways to treat children and young adults with acute lymphocytic leukemia (ALL).
Peter Cole, MD
University of Medicine and Dentistry New Jersey
United States: Food and Drug Administration
|Cancer Institute of New Jersey||New Brunswick, New Jersey 08901|